These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 33801154)

  • 21. Long-term virological outcome in children receiving first-line antiretroviral therapy.
    Chandrasekaran P; Shet A; Srinivasan R; Sanjeeva GN; Subramanyan S; Sunderesan S; Ramesh K; Gopalan B; Suresh E; Poornagangadevi N; Hanna LE; Chandrasekar C; Wanke C; Swaminathan S
    AIDS Res Ther; 2018 Nov; 15(1):23. PubMed ID: 30477526
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alarming increase in pretreatment HIV drug resistance in children living in sub-Saharan Africa: a systematic review and meta-analysis.
    Boerma RS; Sigaloff KC; Akanmu AS; Inzaule S; Boele van Hensbroek M; Rinke de Wit TF; Calis JC
    J Antimicrob Chemother; 2017 Feb; 72(2):365-371. PubMed ID: 27999070
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Should We Be Testing for Baseline Integrase Resistance in Patients Newly Diagnosed With Human Immunodeficiency Virus?
    Koullias Y; Sax PE; Fields NF; Walensky RP; Hyle EP
    Clin Infect Dis; 2017 Oct; 65(8):1274-1281. PubMed ID: 28605418
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical Impact and Cost-effectiveness of Genotype Testing at Human Immunodeficiency Virus Diagnosis in the United States.
    Hyle EP; Scott JA; Sax PE; Millham LRI; Dugdale CM; Weinstein MC; Freedberg KA; Walensky RP
    Clin Infect Dis; 2020 Mar; 70(7):1353-1363. PubMed ID: 31055599
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rates of switching to second-line antiretroviral therapy and impact of delayed switching on immunologic, virologic, and mortality outcomes among HIV-infected adults with virologic failure in Rakai, Uganda.
    Ssempijja V; Nakigozi G; Chang L; Gray R; Wawer M; Ndyanabo A; Kasule J; Serwadda D; Castelnuovo B; Hoog AV; Reynolds SJ
    BMC Infect Dis; 2017 Aug; 17(1):582. PubMed ID: 28830382
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HIV drug resistance in sub-Saharan Africa: public health questions and the potential role of real-world data and mathematical modelling.
    de Waal R; Lessells R; Hauser A; Kouyos R; Davies MA; Egger M; Wandeler G
    J Virus Erad; 2018 Nov; 4(Suppl 2):55-58. PubMed ID: 30515315
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-Utility Analysis of Dolutegravir- Versus Efavirenz-Based Regimens as a First-Line Treatment in Adult HIV/AIDS Patients in Ethiopia.
    Belay YB; Ali EE; Chung KY; Gebretekle GB; Sander B
    Pharmacoecon Open; 2021 Dec; 5(4):655-664. PubMed ID: 34133017
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacy refill data can be used to predict virologic failure for patients on antiretroviral therapy in Brazil.
    Martin D; Luz PM; Lake JE; Clark JL; Campos DP; Veloso VG; Moreira RI; Cardoso SW; Klausner JD; Grinsztejn B
    J Int AIDS Soc; 2017 Jun; 20(1):21405. PubMed ID: 28605172
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Simplifying switch to second-line antiretroviral therapy in sub Saharan Africa: predicted effect of using a single viral load to define efavirenz-based first-line failure.
    Shroufi A; Van Cutsem G; Cambiano V; Bansi-Matharu L; Duncan K; Murphy RA; Maman D; Phillips A
    AIDS; 2019 Aug; 33(10):1635-1644. PubMed ID: 31305331
    [TBL] [Abstract][Full Text] [Related]  

  • 30. What Should We Do When HIV-positive Children Fail First-line Combination Antiretroviral Therapy? A Comparison of 4 ART Management Strategies.
    Patten G; Schomaker M; Davies MA; Rabie H; van Zyl G; Technau K; Eley B; Boulle A; Van Dyke RB; Patel K; Sipambo N; Wood R; Tanser F; Giddy J; Cotton M; Nuttall J; Essack G; Karalius B; Seage G; Sawry S; Egger M; Fairlie L;
    Pediatr Infect Dis J; 2019 Apr; 38(4):400-405. PubMed ID: 30882732
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The cost-effectiveness of antiretroviral treatment in Khayelitsha, South Africa--a primary data analysis.
    Cleary SM; McIntyre D; Boulle AM
    Cost Eff Resour Alloc; 2006 Dec; 4():20. PubMed ID: 17147833
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pretreatment HIV Drug Resistance and Virologic Outcomes to First-Line Antiretroviral Therapy in Peru.
    Soria J; Mugruza R; Levine M; León SR; Arévalo J; Ticona E; Beck IA; Frenkel LM
    AIDS Res Hum Retroviruses; 2019 Feb; 35(2):150-154. PubMed ID: 30560685
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Does directly administered antiretroviral therapy represent good value for money in sub-Saharan Africa? A cost-utility and value of information analysis.
    Uthman RT; Sutton AJ; Jackson LJ; Uthman OA
    PLoS One; 2018; 13(1):e0191465. PubMed ID: 29360841
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High levels of pretreatment and acquired HIV drug resistance in Nicaragua: results from the first nationally representative survey, 2016.
    Girón-Callejas A; García-Morales C; Mendizabal-Burastero R; Román M; Tapia-Trejo D; Pérez-García M; Quiroz-Morales VS; Juárez SI; Ravasi G; Vargas C; Gutiérrez R; Romero L; Solórzano A; Sajquim E; Northbrook S; Ávila-Ríos S; Reyes-Terán G
    J Int AIDS Soc; 2019 Dec; 22(12):e25429. PubMed ID: 31860167
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effectiveness of Once/Day Dolutegravir Plus Boosted Darunavir as a Switch Strategy in Heavily Treated Patients with Human Immunodeficiency Virus.
    Navarro J; Santos JR; Silva A; Burgos J; Falcó V; Ribera E; Imaz A; Curran A
    Pharmacotherapy; 2019 Apr; 39(4):501-507. PubMed ID: 30723941
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis.
    Gupta RK; Gregson J; Parkin N; Haile-Selassie H; Tanuri A; Andrade Forero L; Kaleebu P; Watera C; Aghokeng A; Mutenda N; Dzangare J; Hone S; Hang ZZ; Garcia J; Garcia Z; Marchorro P; Beteta E; Giron A; Hamers R; Inzaule S; Frenkel LM; Chung MH; de Oliveira T; Pillay D; Naidoo K; Kharsany A; Kugathasan R; Cutino T; Hunt G; Avila Rios S; Doherty M; Jordan MR; Bertagnolio S
    Lancet Infect Dis; 2018 Mar; 18(3):346-355. PubMed ID: 29198909
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effectiveness, Safety, and Costs of Dolutegravir/Abacavir/Lamivudine Single-Tablet Regimen in a Real-Life Cohort of HIV-1 Adult Infected Patients.
    Rodriguez-Gonzalez CG; Chamorro-de-Vega E; Ortega-Navarro C; Alonso R; Herranz-Alonso A; Sanjurjo-Saez M
    Ann Pharmacother; 2020 Jul; 54(7):633-643. PubMed ID: 31910643
    [No Abstract]   [Full Text] [Related]  

  • 38. HIV drug resistance surveillance for prioritizing treatment in resource-limited settings.
    Walensky RP; Weinstein MC; Yazdanpanah Y; Losina E; Mercincavage LM; Touré S; Divi N; Anglaret X; Goldie SJ; Freedberg KA;
    AIDS; 2007 May; 21(8):973-82. PubMed ID: 17457091
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The relative contributions of HIV drug resistance, nonadherence and low-level viremia to viremic episodes on antiretroviral therapy in sub-Saharan Africa.
    Inzaule SC; Bertagnolio S; Kityo CM; Siwale M; Akanmu S; Wellington M; de Jager M; Ive P; Mandaliya K; Stevens W; Boender TS; Ondoa P; Sigaloff KCE; Rinke de Wit TF; Hamers RL
    AIDS; 2020 Aug; 34(10):1559-1566. PubMed ID: 32675566
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost effectiveness of single-dose nevirapine regimen for mothers and babies to decrease vertical HIV-1 transmission in sub-Saharan Africa.
    Marseille E; Kahn JG; Mmiro F; Guay L; Musoke P; Fowler MG; Jackson JB
    Lancet; 1999 Sep; 354(9181):803-9. PubMed ID: 10485721
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.